On Saturday, Vicente Verez Bencomo, general director of the Finlay Vaccines Institute in Havana, informed that an independent committee determined a 62-percent efficacy of the Cuban vaccine candidate, which exceeds the 50 percent established by WHO to become a vaccine, a success Cuban President Miguel Diaz-Canel highlighted on social media.
France Info, LCI and France 24, as well as Le Parisien newspaper, echoed the result after 13 months of work in Cuba on a vaccine candidate that is expected to protect the country’s entire population from Covid-19 before the end of this year.
Likewise, those media outlets quoted statements in which Verez said that the positive impact of the vaccine candidate Soberana 02 was determined in relation to the administration of two doses, so it is very likely that it increases by adding a third immune booster shot with Soberana Plus.
France Info recalled that the Cuban vaccine candidate Abdala is also in the third and final phase of clinical trials in humans. Cuba has developed five vaccine candidates so far.
France 24 published that more than four million doses have already been administrated in emergency health interventions in Havana and other Cuban provinces.
jg/iff/oda/wmr/gdc
